Table 3.
Sample validation results and serum protein identifications.
| I | |||
|---|---|---|---|
| A: Samples validateda (N) | B: Validationa database (N) | C: Effect sizeb Cohen's d | D: % Correct True pathology |
| Pancreatic cancer stage IIB (N = 8) & non-cancer (control) (N = 8) | Pancreatic cancer stage IIB (N = 11) vs. non-cancer (control: N = 14) | 4.4 | 100% (16/16) |
| Pancreatic cancer stages IIA & IIB (N = 10) & non-cancer (control) (N = 8) | Pancreatic cancer stages IIA & IIB (N = 13) vs. non-cancer (control: N = 14) | 4.6 | 100% (18/18) |
| Pancreatic cancer stages I, IIA & IIB (N = 12) & non-cancer (control) (N = 8) | Pancreatic cancer stages I, IIA & IIB (N = 16) vs. non-cancer (control: N = 14) | 4.5 | 100% (20/20) |
| Pancreatitis(N = 5) & non-cancer (control) (N = 8) | Pancreatitis (N = 9) vs. non-cancer (control: N = 14) | 4.4 | 100% (13/13) |
| Pancreatitis (N = 5) & pancreatic cancer stage IIB (N = 8) | Pancreatitis (N = 9) vs. pancreatic cancer stage IIB (N = 11) | 4.0 | 100% (13/13) |
| II | |||||
|---|---|---|---|---|---|
| Protein identified | # Identified sequences Control [Cancerc] | Protein identified | # Identified sequences Control [Cancerc] | Protein identified | # Identified sequences Control [Cancerc] |
| Ig heavy chaind | 323 [268] | RYR2e | 39 [0] | SMARCAL1e | 7 [6] |
| Cytochrome c oxidased | 102 [103] | INSRd | 19[17] | TICRR | 8 [5] |
| NEBd | 40 [m] | PCLO | 26 [10] | ANKRD12e | 11 [1] |
| Ig light chaind | 105 [48] | TENM3 | 9 [19] | SUPV3L1e | 9 [3] |
| OBSCNd | 78 [35] | CSMD3e | 17 [10] | TMC2 | 12 [4] |
| TTNd | 38 [70] | CNTNAP4e | 17 [9] | WDR90 | 12 [0] |
| MUC16d | 33 [51] | MACF1e | 25 [1] | SSPO | 6 [5] |
| KMT2Ae | 12 [69] | WDFY3e | 15 [8] | BCL9Ld | 2 [9] |
| SYNE1e | 26 [55] | NSD1e | 14 [9] | NADHe | 6 [4] |
| BAI2e | 52 [22] | TRPM1e | 21 [2] | PITPNM3e | 9 [1] |
| CACNA1Ae | 22 [38] | VWA5B2e | 18 [3] | Cytochromed | 4 [5] |
| EIF4G1e | 18 [41] | RLTPR | 0 [21] | SLC35A2 | 9 [0] |
| MYCBP2 | 0 [51] | COL19A1 | 19 [0] | DNAH3 | 3 [4] |
| PLECd | 49 [2] | SHANK1e | 12 [7] | PLXNB1e | 2 [5] |
| SYNE2e | 0 [50] | TCRd | 6 [12] | SSTR5d | 3 [4] |
| ABCA1d | 30 [15] | BSN | 17 [0] | MUC19 | 3 [3] |
| DMDe | 23 [22] | DISP1d | 3 [13] | AMHe | 6 [0] |
| CEP164e | 21 [20] | ACACBe | 7 [8] | HLA-Bd | 3 [1] |
| NPNTe | 20 [21] | MUC2d | 14 [0] | MHCd | 4 [0] |
a
Blind samples are not members of the validation database against which they were tested;
b
observed between blinded sample groups.
c
Pancreatic cancer stage IIB
d
pancreatic cancer related
e
other cancer related, unique sequence segments range (3-273), 60 peaks (700-940)m/Z.